RESECT

Resect
Transurethral REsection and Single instillation intra-vesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT)
Improving quality in TURBT surgery.
 

RESECT is a new GLOBAL prospective multi-centre international observational study starting in 2020.

CLICK ON THE RED BANNER BELOW TO PRE-REGISTER:

Link for RESECT

Status Update – 19/07/2020: 487 collaborators have now pre-registered to take part in RESECT from 50 countries across the globe! The RESECT protocol is being finalised. We are working hard to ensure the study can launch later this year as clinic practice returns to normal after the COVID-19 pandemic.

Aim

RESECT aims to answer some key UNKNOWNS: 

  • What things should we measure to determine TURBT quality?
  • What rate of achievement should we aim for in our practice?
  • What factors are associated with better achievement of TURBT quality? 
  • Does reporting and comparing our TURBT quality make us do it better?

Ultimately we want to determine meaningful TURBT quality indicators, find out how these are most usefully measured and then use these to drive up quality across the world. 

 

Who can take part?
Anybody anywhere in the world who works in a centre performing TURBT can take part.

Background
There is strong evidence which guides the optimal management of non muscle invasive bladder cancer (NMIBC), particularly in how the initial resection should be performed and in the use of single dose postoperative intravesical chemotherapy with Mitomycin-C (SI-MMC) (or equivalent agent). We know that achieving a “good quality” NMIBC surgery results in improved accuracy of diagnosis and reduced recurrence rates. The international guidelines include clear and easily measurable recommendations related to transurethral resection of bladder tumour (TURBT) and MMC use, based on best available evidence. Despite this there is anecdotal evidence that practice varies widely and this may impact on oncological outcomes.

Benefits of getting involved:

  • Registration is simple and should avoid formal ethical approvals: In the UK the study will qualify as a “service evaluation” and will be exempt from needing ethical approval, although individual centres in other countries will have to follow local governance rules.
  • Taking part is simple: you will be part of what could potential be the largest prospective audit of TURBT surgery ever performed.
  • Use the database to record and track your own and your hospitals TURBT training, performance and outcomes.
  • Anybody who works in a center performing TURBT surgery can quickly and easily enter the data into our user-friendly online secure database.
  • All contributors will receive Pubmed indexed collaborator authorship.
  • The highest recruiting individuals will be invited onto the writing committee. The more patients recruited the higher up the collaborative list and you will gain preference for presentation of the study findings at conferences.
  • Returns on this will be fast- our previous studies MIMIC and IDENTIFY are proof
  • RESECT is listed on the national healthcare quality improvement partnership (HQIP) Directory and will count towards audit requirements for UK ARCP and re-validation.

Proudly Supported by: